Halogen bonds form the basis for selective P-TEFb inhibition by DRB
about
The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor bComparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype SelectivityThe σ-hole phenomenon of halogen atoms forms the structural basis of the strong inhibitory potency of C5 halogen substituted glucopyranosyl nucleosides towards glycogen phosphorylase bThe CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508Structure-kinetic relationship study of CDK8/CycC specific compoundsSelective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitorsIsomeric mono-, di-, and tri-bromobenzo-1H-triazoles as inhibitors of human protein kinase CK2α.A Cyclin T1 point mutation that abolishes positive transcription elongation factor (P-TEFb) binding to Hexim1 and HIV tatInhibition of cdk9 during herpes simplex virus 1 infection impedes viral transcriptionHalogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery.Discovery of novel 5-fluoro-N(2),N(4)-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9.Determining the Functions of HIV-1 Tat and a Second Magnesium Ion in the CDK9/Cyclin T1 Complex: A Molecular Dynamics Simulation Study.HEXIM1 controls satellite cell expansion after injury to regulate skeletal muscle regenerationEffects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvaeRRP1B is a metastasis modifier that regulates the expression of alternative mRNA isoforms through interactions with SRSF1.A kinase-independent activity of Cdk9 modulates glucocorticoid receptor-mediated gene induction.Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity?Halogen bonding for rational drug design and new drug discovery.Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Molecular recognition in chemical and biological systems.Overview of CDK9 as a target in cancer research.Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.Computer-aided design, synthesis and validation of 2-phenylquinazolinone fragments as CDK9 inhibitors with anti-HIV-1 Tat-mediated transcription activity.Relationships between hydrogen bonds and halogen bonds in biological systems.CDK9 and SPT5 proteins are specifically required for expression of herpes simplex virus 1 replication-dependent late genes.A quantum mechanics-based halogen bonding scoring function for protein-ligand interactions.Identification of novel inhibitors against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.Use of Chemicals to Inhibit DNA Replication, Transcription, and Protein Synthesis to Study Zygotic Genome Activation.Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex.Use of phenoxyaniline analogs to generate biochemical insights into polybrominated diphenyl ether interaction with CYP2B enzymes.Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies.
P2860
Q27672752-69A7AD70-87F5-4E58-90A7-2095A6277A76Q27675539-65D69346-22F6-4258-98BD-F2950F3C7F7EQ27676843-87F367E4-A795-40E7-92D3-434554EBD037Q27676963-7BF7FEDC-5BA5-47E9-AE09-733B8E3CB2B3Q27677859-F4ED8DD8-BD5B-4DF5-B421-7713F9C6D227Q34295282-36F5E487-7232-42BA-986B-9295C361B59EQ34479175-867BBEE2-E207-432B-9F8C-06D562A50401Q34486331-9F24882F-C5C0-446B-89E0-9BD10491A44EQ35036881-E8B0A4A7-A3BF-4276-8024-B15751211697Q35181268-846E0CE5-CDA6-4486-A10F-189BA14D266FQ35524888-B93E373C-D584-40AB-A2AB-A64BFB72201DQ35536739-DC6188FA-7E81-4266-8A05-E8DD5B653436Q36357842-B14D7215-B4F2-4126-A9D1-58B7200FEFAEQ37467587-6524B7F4-B4ED-420A-87BC-D00BC407C8AAQ37585662-12AC60C8-CF18-473D-BEA6-64D85F38B993Q37701748-22986B2D-C09A-458A-9C5E-1D6AE6683772Q37933073-2D2F4E56-F49A-4B7A-BA7D-77118D143DC4Q37998524-C88BF33E-F018-47D8-8676-D33C50F39947Q38008733-63368BB5-996C-41C1-820C-F78C6CB617C7Q38335784-F301D20A-2863-4D8A-A3D3-3F75F4E3C34FQ38696353-486852E7-A7AD-4A8A-9A40-406F5170963AQ38806786-1ECACBA6-A41B-40AA-9911-7EA773FC9815Q39005055-C51501B4-6598-40DB-9FD1-B0CC27A3CB19Q39073158-FA2E6EA4-881E-43C4-87BE-7379E91E7201Q39210894-D610963B-302E-4699-9523-F0BF43161DC5Q40108637-734FF3A1-FE04-4196-9DE0-181712DDDAB8Q40957448-758A03E0-9B68-459A-A51E-3EAE733A251EQ41457054-437578DA-4988-4EB6-970F-BB8A13700DC9Q45058086-FCFE6838-4C6A-461E-B1BB-CFAF62B5596CQ45741706-21ABE606-C6A4-4CBB-A18F-13773CEBD228Q46246116-7C0C3CD9-F055-4940-AB60-C99B55C272C1Q46420204-9C16DF0C-5B41-4690-A3F9-8E638B82C9B0Q55033883-43239FEA-CC44-4827-9D70-E82CE004019D
P2860
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
@ast
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
@en
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
@nl
type
label
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
@ast
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
@en
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
@nl
prefLabel
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
@ast
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
@en
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
@nl
P3181
P1476
Halogen bonds form the basis for selective P-TEFb inhibition by DRB
@en
P2093
Louise N Johnson
Sonja Baumli
P304
P3181
P356
10.1016/J.CHEMBIOL.2010.07.012
P577
2010-09-01T00:00:00Z